Skip to Content
Merck
  • DNA repair in human pluripotent stem cells is distinct from that in non-pluripotent human cells.

DNA repair in human pluripotent stem cells is distinct from that in non-pluripotent human cells.

PloS one (2012-03-14)
Li Z Luo, Sailesh Gopalakrishna-Pillai, Stephanie L Nay, Sang-Won Park, Steven E Bates, Xianmin Zeng, Linda E Iverson, Timothy R O'Connor
ABSTRACT

The potential for human disease treatment using human pluripotent stem cells, including embryonic stem cells and induced pluripotent stem cells (iPSCs), also carries the risk of added genomic instability. Genomic instability is most often linked to DNA repair deficiencies, which indicates that screening/characterization of possible repair deficiencies in pluripotent human stem cells should be a necessary step prior to their clinical and research use. In this study, a comparison of DNA repair pathways in pluripotent cells, as compared to those in non-pluripotent cells, demonstrated that DNA repair capacities of pluripotent cell lines were more heterogeneous than those of differentiated lines examined and were generally greater. Although pluripotent cells had high DNA repair capacities for nucleotide excision repair, we show that ultraviolet radiation at low fluxes induced an apoptotic response in these cells, while differentiated cells lacked response to this stimulus, and note that pluripotent cells had a similar apoptotic response to alkylating agent damage. This sensitivity of pluripotent cells to damage is notable since viable pluripotent cells exhibit less ultraviolet light-induced DNA damage than do differentiated cells that receive the same flux. In addition, the importance of screening pluripotent cells for DNA repair defects was highlighted by an iPSC line that demonstrated a normal spectral karyotype, but showed both microsatellite instability and reduced DNA repair capacities in three out of four DNA repair pathways examined. Together, these results demonstrate a need to evaluate DNA repair capacities in pluripotent cell lines, in order to characterize their genomic stability, prior to their pre-clinical and clinical use.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Dimethyl sulfate, ≥99%
Sigma-Aldrich
Dimethyl sulfate, ≥99.5%